You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitrendipine
Accession NumberDB01054  (APRD00421)
TypeSmall Molecule
GroupsApproved
DescriptionA calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
Structure
Thumb
Synonyms
1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
BAY e 5009
Bayotensin
Baypress
Bylotensin
Deiten
Nidrel
Nitrendipino
Nitrendipinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BayotensinNot Available
BaypressNot Available
DeitenNot Available
NidrelNot Available
NitrepinNot Available
NitrezicNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9B627AW319
CAS number39562-70-4
WeightAverage: 360.3612
Monoisotopic: 360.132136382
Chemical FormulaC18H20N2O6
InChI KeyInChIKey=PVHUJELLJLJGLN-UHFFFAOYSA-N
InChI
InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of mild to moderate hypertension
PharmacodynamicsNitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding> 99%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nitrendipine Action PathwayDrug actionSMP00382
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9536
Blood Brain Barrier-0.9549
Caco-2 permeable+0.7853
P-glycoprotein substrateSubstrate0.5265
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8313
Renal organic cation transporterNon-inhibitor0.8984
CYP450 2C9 substrateNon-substrate0.8212
CYP450 2D6 substrateNon-substrate0.8931
CYP450 3A4 substrateSubstrate0.7266
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.8037
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9247
Ames testNon AMES toxic0.7334
CarcinogenicityNon-carcinogens0.5186
BiodegradationNot ready biodegradable0.9581
Rat acute toxicity2.3810 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8131
hERG inhibition (predictor II)Non-inhibitor0.9094
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156-160 °CNot Available
water solubilityInsolubleNot Available
logP2.88MASUMATO,K ET AL. (1995)
Caco2 permeability-4.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0142 mg/mLALOGPS
logP3.21ALOGPS
logP2.17ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity96.91 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, “Preparation of solid medicament formulation containing nitrendipine.” U.S. Patent US4724141, issued April, 1980.

US4724141
General ReferencesNot Available
External Links
ATC CodesC08CA08C09BB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nitrendipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nitrendipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nitrendipine.
AcebutololNitrendipine may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nitrendipine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nitrendipine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrendipine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nitrendipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitrendipine.
AliskirenNitrendipine may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine.
AlprenololAlprenolol may increase the hypotensive activities of Nitrendipine.
AmbrisentanNitrendipine may increase the hypotensive activities of Ambrisentan.
AmifostineNitrendipine may increase the hypotensive activities of Amifostine.
AmiodaroneThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine.
AmlodipineAmlodipine may increase the hypotensive activities of Nitrendipine.
AmobarbitalThe metabolism of Nitrendipine can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nitrendipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nitrendipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nitrendipine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nitrendipine.
AprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.
AtazanavirThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Nitrendipine.
AtenololAtenolol may increase the hypotensive activities of Nitrendipine.
AtomoxetineThe metabolism of Nitrendipine can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atosiban.
Atracurium besylateNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nitrendipine.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nitrendipine.
BarbitalThe metabolism of Nitrendipine can be increased when combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Nitrendipine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nitrendipine.
BenmoxinBenmoxin may increase the hypotensive activities of Nitrendipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nitrendipine.
BepridilNitrendipine may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nitrendipine.
BetaxololBetaxolol may increase the hypotensive activities of Nitrendipine.
BethanidineBethanidine may increase the hypotensive activities of Nitrendipine.
BexaroteneThe serum concentration of Nitrendipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nitrendipine.
BimatoprostBimatoprost may increase the hypotensive activities of Nitrendipine.
BisoprololBisoprolol may increase the hypotensive activities of Nitrendipine.
BoceprevirThe metabolism of Nitrendipine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Nitrendipine.
BortezomibThe metabolism of Nitrendipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.
BosentanNitrendipine may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.
BretyliumNitrendipine may increase the hypotensive activities of Bretylium.
BrimonidineNitrendipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nitrendipine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine.
BupranololNitrendipine may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nitrendipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nitrendipine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nitrendipine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nitrendipine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.
CandesartanCandesartan may increase the hypotensive activities of Nitrendipine.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine.
CandoxatrilCandoxatril may increase the hypotensive activities of Nitrendipine.
CaptoprilNitrendipine may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nitrendipine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nitrendipine.
CarteololCarteolol may increase the hypotensive activities of Nitrendipine.
CarvedilolNitrendipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine.
CeliprololNitrendipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nitrendipine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nitrendipine.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nitrendipine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nitrendipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nitrendipine.
CilazaprilNitrendipine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nitrendipine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nitrendipine.
ClarithromycinThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Nitrendipine.
ClemastineThe metabolism of Nitrendipine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nitrendipine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nitrendipine.
ClonidineClonidine may increase the hypotensive activities of Nitrendipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.
ClotrimazoleThe metabolism of Nitrendipine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Nitrendipine.
CobicistatThe metabolism of Nitrendipine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrendipine.
ConivaptanThe serum concentration of Nitrendipine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrendipine.
CrizotinibThe metabolism of Nitrendipine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nitrendipine.
CryptenamineCryptenamine may increase the hypotensive activities of Nitrendipine.
CyclosporineThe metabolism of Nitrendipine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nitrendipine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Nitrendipine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrendipine.
DabrafenibThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Nitrendipine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nitrendipine.
DarunavirThe metabolism of Nitrendipine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine.
DebrisoquinNitrendipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nitrendipine.
DeferasiroxThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nitrendipine can be decreased when combined with Delavirdine.
DeserpidineNitrendipine may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Nitrendipine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nitrendipine.
DiazoxideDiazoxide may increase the hypotensive activities of Nitrendipine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nitrendipine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nitrendipine.
DihydroergotamineThe metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine.
DiltiazemDiltiazem may increase the hypotensive activities of Nitrendipine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nitrendipine.
DorzolamideDorzolamide may increase the hypotensive activities of Nitrendipine.
DoxazosinDoxazosin may increase the hypotensive activities of Nitrendipine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.
DoxycyclineThe metabolism of Nitrendipine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Nitrendipine can be decreased when combined with Dronedarone.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nitrendipine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.
EfavirenzThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nitrendipine.
EfonidipineNitrendipine may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nitrendipine.
EnalaprilEnalapril may increase the hypotensive activities of Nitrendipine.
EnalaprilatNitrendipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nitrendipine.
EpoprostenolNitrendipine may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Nitrendipine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nitrendipine.
ErythromycinThe metabolism of Nitrendipine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Nitrendipine.
Eslicarbazepine acetateThe serum concentration of Nitrendipine can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nitrendipine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Nitrendipine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Nitrendipine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nitrendipine.
EtravirineThe serum concentration of Nitrendipine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine.
FelodipineFelodipine may increase the hypotensive activities of Nitrendipine.
FenoldopamFenoldopam may increase the hypotensive activities of Nitrendipine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine.
FluconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nitrendipine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine.
FluvoxamineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Nitrendipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Nitrendipine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine.
FosphenytoinThe metabolism of Nitrendipine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Nitrendipine.
Fusidic AcidThe serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nitrendipine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nitrendipine.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nitrendipine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nitrendipine.
GuanabenzGuanabenz may increase the hypotensive activities of Nitrendipine.
GuanadrelGuanadrel may increase the hypotensive activities of Nitrendipine.
GuanethidineNitrendipine may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Nitrendipine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Nitrendipine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine.
HexamethoniumNitrendipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nitrendipine.
HexobarbitalThe metabolism of Nitrendipine can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitrendipine.
HydralazineNitrendipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nitrendipine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nitrendipine.
IdelalisibThe serum concentration of Nitrendipine can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Nitrendipine.
ImatinibThe metabolism of Nitrendipine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nitrendipine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nitrendipine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.
IndapamideIndapamide may increase the hypotensive activities of Nitrendipine.
IndenololNitrendipine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Nitrendipine can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Nitrendipine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nitrendipine.
IndoraminNitrendipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Nitrendipine.
IproniazidIproniazid may increase the hypotensive activities of Nitrendipine.
IrbesartanIrbesartan may increase the hypotensive activities of Nitrendipine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nitrendipine.
IsavuconazoniumThe metabolism of Nitrendipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitrendipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nitrendipine.
IsradipineIsradipine may increase the hypotensive activities of Nitrendipine.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nitrendipine.
IvacaftorThe serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nitrendipine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nitrendipine.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Nitrendipine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Nitrendipine.
LabetalolLabetalol may increase the hypotensive activities of Nitrendipine.
LacidipineNitrendipine may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nitrendipine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine.
LatanoprostLatanoprost may increase the hypotensive activities of Nitrendipine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine.
LercanidipineLercanidipine may increase the hypotensive activities of Nitrendipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nitrendipine.
LisinoprilLisinopril may increase the hypotensive activities of Nitrendipine.
LofexidineNitrendipine may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nitrendipine.
LopinavirThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.
LosartanLosartan may increase the hypotensive activities of Nitrendipine.
LovastatinThe metabolism of Nitrendipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Luliconazole.
MacitentanNitrendipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate.
ManidipineNitrendipine may increase the hypotensive activities of Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Nitrendipine.
MebanazineMebanazine may increase the hypotensive activities of Nitrendipine.
MecamylamineMecamylamine may increase the hypotensive activities of Nitrendipine.
MethohexitalThe metabolism of Nitrendipine can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nitrendipine.
MethyldopaMethyldopa may increase the hypotensive activities of Nitrendipine.
Methylene blueMethylene blue may increase the hypotensive activities of Nitrendipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitrendipine.
MethylphenobarbitalThe metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.
MetipranololNitrendipine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Nitrendipine.
MetoprololMetoprolol may increase the hypotensive activities of Nitrendipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine.
MibefradilNitrendipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nitrendipine.
MifepristoneThe metabolism of Nitrendipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nitrendipine.
MinaprineMinaprine may increase the hypotensive activities of Nitrendipine.
MinoxidilMinoxidil may increase the hypotensive activities of Nitrendipine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nitrendipine.
MitotaneThe serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine.
MivacuriumNitrendipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Nitrendipine.
ModafinilThe serum concentration of Nitrendipine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Nitrendipine.
MolsidomineMolsidomine may increase the hypotensive activities of Nitrendipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nitrendipine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Nitrendipine.
MoxonidineNitrendipine may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nitrendipine.
NadololNitrendipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Nitrendipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrendipine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nitrendipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nitrendipine.
NebivololNitrendipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Nitrendipine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Nitrendipine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Nitrendipine.
NetupitantThe serum concentration of Nitrendipine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Nitrendipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Nitrendipine.
NicardipineNicardipine may increase the hypotensive activities of Nitrendipine.
NicorandilNitrendipine may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrendipine.
NiguldipineNitrendipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nitrendipine.
NilvadipineNitrendipine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Nitrendipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.
NisoldipineNisoldipine may increase the hypotensive activities of Nitrendipine.
NitroprussideNitrendipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nitrendipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine.
ObinutuzumabNitrendipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nitrendipine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nitrendipine.
OlaparibThe metabolism of Nitrendipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Nitrendipine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Nitrendipine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine.
OsimertinibThe serum concentration of Nitrendipine can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine.
OxprenololNitrendipine may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nitrendipine.
PalbociclibThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nitrendipine.
PargylineNitrendipine may increase the hypotensive activities of Pargyline.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.
PenbutololNitrendipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine.
PentobarbitalThe metabolism of Nitrendipine can be increased when combined with Pentobarbital.
PentoliniumNitrendipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitrendipine.
PerindoprilPerindopril may increase the hypotensive activities of Nitrendipine.
PhenelzinePhenelzine may increase the hypotensive activities of Nitrendipine.
PheniprazinePheniprazine may increase the hypotensive activities of Nitrendipine.
PhenobarbitalThe metabolism of Nitrendipine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Nitrendipine.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nitrendipine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitrendipine.
PhentolaminePhentolamine may increase the hypotensive activities of Nitrendipine.
PhenytoinThe metabolism of Nitrendipine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrendipine.
PinacidilNitrendipine may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Nitrendipine.
PirlindolePirlindole may increase the hypotensive activities of Nitrendipine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitrendipine.
PolythiazideNitrendipine may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nitrendipine.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nitrendipine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.
PrazosinPrazosin may increase the hypotensive activities of Nitrendipine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nitrendipine.
PrimidoneThe metabolism of Nitrendipine can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nitrendipine.
PropranololPropranolol may increase the hypotensive activities of Nitrendipine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrendipine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Nitrendipine.
QuinaprilQuinapril may increase the hypotensive activities of Nitrendipine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Nitrendipine.
QuinineQuinine may increase the hypotensive activities of Nitrendipine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Nitrendipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nitrendipine.
RamiprilRamipril may increase the hypotensive activities of Nitrendipine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nitrendipine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrendipine.
RanolazineThe metabolism of Nitrendipine can be decreased when combined with Ranolazine.
RapacuroniumNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Nitrendipine.
RemikirenRemikiren may increase the hypotensive activities of Nitrendipine.
RescinnamineNitrendipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nitrendipine.
RifabutinThe metabolism of Nitrendipine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Nitrendipine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Nitrendipine.
RifapentineThe metabolism of Nitrendipine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.
RiociguatNitrendipine may increase the hypotensive activities of Riociguat.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Nitrendipine.
RitonavirThe metabolism of Nitrendipine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Nitrendipine.
RituximabNitrendipine may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nitrendipine.
SafrazineSafrazine may increase the hypotensive activities of Nitrendipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nitrendipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nitrendipine.
SaprisartanNitrendipine may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Nitrendipine.
SecobarbitalThe metabolism of Nitrendipine can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Nitrendipine.
SelexipagNitrendipine may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nitrendipine.
SildenafilSildenafil may increase the antihypertensive activities of Nitrendipine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.
SilodosinSilodosin may increase the hypotensive activities of Nitrendipine.
SiltuximabThe serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nitrendipine can be increased when it is combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nitrendipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine.
SitaxentanNitrendipine may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nitrendipine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nitrendipine.
SpiraprilNitrendipine may increase the hypotensive activities of Spirapril.
St. John's WortThe serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nitrendipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nitrendipine.
SulfisoxazoleThe metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine.
TadalafilTadalafil may increase the antihypertensive activities of Nitrendipine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nitrendipine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nitrendipine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine.
TelaprevirThe metabolism of Nitrendipine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Nitrendipine.
TelithromycinThe metabolism of Nitrendipine can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Nitrendipine.
TemocaprilNitrendipine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.
TerazosinTerazosin may increase the hypotensive activities of Nitrendipine.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine.
TerlipressinNitrendipine may increase the hypotensive activities of Terlipressin.
ThiamylalThe metabolism of Nitrendipine can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Nitrendipine can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine.
TiboloneNitrendipine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine.
TiclopidineThe metabolism of Nitrendipine can be decreased when combined with Ticlopidine.
TicrynafenNitrendipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Nitrendipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nitrendipine.
TocilizumabThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.
TolazolineTolazoline may increase the hypotensive activities of Nitrendipine.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nitrendipine.
ToloxatoneToloxatone may increase the hypotensive activities of Nitrendipine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrendipine.
TorasemideTorasemide may increase the hypotensive activities of Nitrendipine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nitrendipine.
TrandolaprilTrandolapril may increase the hypotensive activities of Nitrendipine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitrendipine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine.
TravoprostTravoprost may increase the hypotensive activities of Nitrendipine.
TreprostinilTreprostinil may increase the hypotensive activities of Nitrendipine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nitrendipine.
TrimazosinNitrendipine may increase the hypotensive activities of Trimazosin.
TrimethaphanNitrendipine may increase the hypotensive activities of Trimethaphan.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine.
UdenafilUdenafil may increase the antihypertensive activities of Nitrendipine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nitrendipine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine.
UnoprostoneNitrendipine may increase the hypotensive activities of Unoprostone.
Ursodeoxycholic acidUrsodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ValsartanValsartan may increase the hypotensive activities of Nitrendipine.
VardenafilVardenafil may increase the antihypertensive activities of Nitrendipine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nitrendipine.
VenlafaxineThe metabolism of Nitrendipine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nitrendipine.
VerapamilThe metabolism of Nitrendipine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Nitrendipine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nitrendipine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nitrendipine.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nitrendipine.
XylometazolineNitrendipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Nitrendipine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nitrendipine.
ZiprasidoneThe metabolism of Nitrendipine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23